Business Wire

PA-BOOMI

15.4.2024 15:01:27 CEST | Business Wire | Press release

Share
Boomi Discovery Report Reveals More Than Half of Enterprises Invest in GenAI for Integration and Automation

Boomi™, the intelligent integration and automation leader, today announced findings from its Boomi Discovery Report, commissioned by 451 Research.1 The report, based on perspectives from 650 business and IT leaders across a broad range of industries, outlines how enterprises are using Generative AI (GenAI) to integrate systems and automate processes, and how this has helped their business operations as a result.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415795607/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Boomi Discovery Report Reveals More Than Half of Enterprises Invest in GenAI for Integration and Automation (Graphic: Business Wire)

Every business is grappling with growing digital fragmentation – from application sprawl and disconnect between departments, to rising costs and skills shortages. GenAI delivers the promise of more efficient and cost-effective operations and improved customer and employee experiences, but only for businesses that embrace it.

According to the Boomi Discovery Report, organizations are seeing GenAI’s immediate impact on integration. More than half of respondents (55%) said GenAI was very important for integrating data, applications, and processes. Moreover, the global drivers of AI adoption included increased productivity (which 44% of executives cited), increased sales and revenue growth (40%), and improved customer experience (39%).

However, respondents acknowledged the complexity that’s often associated with integration. Many times, integrating data and systems can bring challenges that prompt security and privacy concerns (42%), data quality and availability challenges (42%), and model training, accuracy, and reliability (31%). According to the report, 90% of respondents agree that GenAI has the potential to improve the speed and quality of the development and automation of data, application, and process integrations.

“The ability to seamlessly integrate and automate business processes has long been a top priority for many enterprises,” said Steve Lucas, CEO at Boomi. “As organizations scale and continue to navigate unforeseen business challenges, it will become more difficult to keep track of all the data, technology, and processes necessary to achieve business goals. Generative AI can be a powerful tool for today’s enterprises, streamlining valuable integration and automation practices and freeing IT teams to focus on innovation. Finding ways to leverage GenAI effectively is the next business prerogative. Boomi is not only helping get businesses ready for it, but also leading the GenAI charge in the integration and automation space."

Additional key findings from the report include:

  • IT leaders have more trust in GenAI than business leaders: IT CxOs have a higher rate of trust – 82% either “completely” or “somewhat” trust the output of GenAI, versus 63% of business CxOs.
  • Accuracy and consistency are major factors driving trust in GenAI: More than half of business leaders (57%) cited accuracy and quality of AI outputs as a factor in their trust of AI. Just under half (48%) cited consistency and reliability as an AI trust factor.
  • Enterprise execs see tremendous value in GenAI: Leaders cited improved process accuracy and consistency (38%), cost reduction (38%), innovation and creativity (34%), streamlined operations (31%), optimized resources (28%), and enablement of competitive advantage (27%) as top potential benefits for leveraging GenAI.
  • GenAI has widespread value for integrations: All respondents believe that virtually any type of integration would benefit from GenAI-assisted integration platforms.

“Integration and automation are the foundation upon which enterprises build business agility,” said Matt McLarty, CTO at Boomi. “However, integrating and automating systems isn’t always easy. This is why it pays off to have a unified approach for both. With a unified platform, powered by AI technology, enterprises can gain the advantages of comprehensive integration and automation while mitigating unwanted complexity.”

For more information on the 2024 Boomi Discovery Report, click here.

Additional Resources

About Boomi

Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.

© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

Methodology

The findings presented in this report draw on a survey fielded in North America and Europe in Q4 2023. The survey targeted 650 business and IT decision-makers/influencers in companies ranging in size from under 100 to over 25,000 employees, and $2 million to over $10 billion in annual revenue. The study prioritized respondents with intimate knowledge of automation and integration technology across a broad range of diverse industries asking them about their perception of, and propensity to use, AI technologies of various types, but more specifically about their use of GenAI. The job descriptions of respondents were a mix of executives ranging from Analyst/Manager grade to C-level Executives. This report also draws on contextual knowledge of additional research conducted by S&P Global Market Intelligence.

 

 

1Source: The Impact of AI on Enterprise Integration and Automation, 451 Research, a part of S&P Global Market Intelligence and Boomi, 2024. All Rights Reserved

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415795607/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye